Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 Polyunsaturated Fatty Acids in HFpEF (Myocardial Energy Consumption and LV Remodeling)
ChiCTR2300078551Phase 4Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Dec 2023
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial in heart failure with preserved ejection fraction (HFpEF) comparing Omega-3 PUFA arm with Placebo arm (2 arms). Primary endpoint: Myocardial energy expenditure. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
omega-3-acid triglycerides
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ChiCTR2300078551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078551.